Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZS801 injection in moderate-to-severe hemophilia B
ChiCTR2200066330Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2022
- Modality
- Small Molecules, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZS801 in hemophilia B (HB) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse events, Vital signs and 3 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
ZS801
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on ChiCTR2200066330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066330.